Jasper Hellweg
Stock Analyst at Argus Research
(2.77)
# 1,792
Out of 4,873 analysts
89
Total ratings
51.43%
Success rate
18.43%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Downgrades: Hold | n/a | $126.31 | - | 4 | Apr 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $289.94 | +37.96% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $91.52 | +63.90% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $48.42 | +23.92% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $522.27 | +124.02% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $450.27 | +22.15% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $70.54 | +20.50% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $70.73 | +76.73% | 1 | Feb 1, 2024 | |
| MRNA Moderna | Maintains: Buy | $160 → $140 | $26.80 | +422.39% | 4 | Sep 13, 2023 | |
| ABBV AbbVie | Downgrades: Hold | n/a | $185.55 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $200 | $157.77 | +26.77% | 6 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $17.09 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $158.58 | +82.87% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $120.42 | -16.96% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $262.53 | +12.37% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $6.77 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $179.90 | -24.96% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $30.59 | - | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $26.75 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $261.81 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $118.29 | - | 2 | Mar 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $39.90 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $379.02 | -59.11% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $172.66 | -47.87% | 1 | Sep 19, 2018 |
Biogen
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $126.31
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $289.94
Upside: +37.96%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $91.52
Upside: +63.90%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $48.42
Upside: +23.92%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $522.27
Upside: +124.02%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $450.27
Upside: +22.15%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $70.54
Upside: +20.50%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $70.73
Upside: +76.73%
Moderna
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $26.80
Upside: +422.39%
AbbVie
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $185.55
Upside: -
Jun 17, 2022
Maintains: Buy
Price Target: $225 → $200
Current: $157.77
Upside: +26.77%
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $17.09
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $158.58
Upside: +82.87%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $120.42
Upside: -16.96%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $262.53
Upside: +12.37%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $6.77
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $179.90
Upside: -24.96%
Sep 4, 2020
Downgrades: Hold
Price Target: n/a
Current: $30.59
Upside: -
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $26.75
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $261.81
Upside: -
Mar 24, 2020
Downgrades: Hold
Price Target: n/a
Current: $118.29
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $39.90
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $379.02
Upside: -59.11%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $172.66
Upside: -47.87%